Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib-first treatment algorithm with escalation to omalizumab in adults with chronic spontaneous urticaria
jRCT2031260510Recruiting
- Sponsor
- Novartis
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of remibrutinib and omalizumab in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Novartis. Primary endpoint: Proportion of participants achieving UAS7 <= 6. Started Sep 2026; status: recruiting.
02
Drugs
remibrutinibomalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2031260510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260510.